Interl 1al Application No PCT/IB2004/003082

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K31/40 A61K31/426 A61K45/06 A61P3/10

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC  $\,7\,$  A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, CHEM ABS Data, BIOSIS, EMBASE, WPI Data, PAJ

	ENTS CONSIDERED TO BE RELEVANT		
ategory °	Citation of document, with indication, where appropriate, of the	ne relevant passages	Relevant to claim No.
X	US 6 548 481 B1 (DEMUTH HANS-U 15 April 2003 (2003-04-15) claims 1,5,13,14 column 1, line 66 - column 2, column 7, paragraph 2		1-12,15, 16,20-26
Y	US 2003/119736 A1 (DEMUTH HANS AL) 26 June 2003 (2003-06-26) page 5, column 2, paragraph 5 column 1, paragraph 1 claims		1–26
Y	US 2003/162820 A1 (DEMUTH HANS AL) 28 August 2003 (2003-08-28 claims	G-ULRICH ET	1-26
X Fu	ther documents are listed in the continuation of box C.	χ Patent family members are listed	in annex.
"A" docum cons "E" earlier filling "L" docum which citati "O" docum other "P" docum	categories of cited documents:  nent defining the general state of the art which is not idered to be of particular relevance or document but published on or after the international date determined the company of the cited to establish the publication date of another on or other special reason (as specified) on the cited to an oral disclosure, use, exhibition or or means the priority of the international filing date but than the priority date claimed	"T" later document published after the int or priority date and not in conflict with cited to understand the principle or the invention of particular relevance; the cannot be considered novel or cannot involve an inventive step when the discument of particular relevance; the cannot be considered to involve an indocument is combined with one or ments, such combination being obvious in the art.  "&" document member of the same patents."	n the application but theory underlying the claimed invention of the considered to coument is taken alone claimed invention invention or other such docu-
	e actual completion of the international search  5 June 2005	Date of mailing of the international se 15/06/2005	arch report
Name and	l mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk	Authorized officer	

Inter 1al Application No PCT/IB2004/003082

	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Υ	GOODMAN G A ET AL: "GOODMAN and GILMAN'S The Pharmacological Basis of Therapeutics, (sulfonylureas, biguanides, thiazolidinediones, alpha-glucosidase inhibitors)"  2001, PHARMACOLOGICAL BASIS OF THERAPEUTICS, GOODMAN GILMAN'S PHARMACOLOGICAL BASIS OF THERAPEUTICS, NEW YORK, MACMILLAN PUBL. CIE, US, PAGE(S) 1701-1707, XP002330634 page 1701, column 2, paragraph 4 - page 17047, column 2, paragraph 3 page 1705, column 1, paragraph 3 page 1706, column 1, paragraph 1 page 1706, column 1, paragraph 2 - page 1706, column 2, paragraph 5 page 1706, column 2, paragraph 6 - page 1707, column 1, paragraph 2	1-26
A	US 2003/139434 A1 (BALKAN BORK ET AL) 24 July 2003 (2003-07-24) the whole document	1-26
X,P	DE 299 24 609 U1 (PROBIODRUG AG) 22 April 2004 (2004-04-22) claims	1-26
X,P	WO 2004/031374 A (PROBIODRUG AG; KUEHN-WACHE, KERSTIN; BAER, JOACHIM; DEMUTH, HANS-ULRIC) 15 April 2004 (2004-04-15) page 53 page 75, paragraph 3 - paragraph 4	1-26

......ational application No. PCT/IB2004/003082

Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 1, 2, 5, 6 and 8-14 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
. 3. Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
see additional sheet
1. X As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest  The additional search fees were accompanied by the applicant's protest.  X  No protest accompanied the payment of additional search fees.

#### FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-12, 23-25 (all partially), 13, 14

A method or pharmaceutical composition for glycaemic control in a mammal, comprising the administration of glutaminyl thiazolidine or glutaminyl pyrrolidine, or a pharmaceutically acceptable salt thereof, and an alpha glucosidase inhibitor.

2. claims: 1-12, 23-25, (all partially), 15, 16, 20-22, 26

A method or pharmaceutical composition for glycaemic control in a mammal, comprising the administration of glutaminyl thiazolidine or glutaminyl pyrrolidine, or a pharmaceutically acceptable salt thereof, and a biguanide.

3. claims: 1-12, 23-25, (all partially), 17

A method or pharmaceutical composition for glycaemic control in a mammal, comprising the administration of glutaminyl thiazolidine or glutaminyl pyrrolidine, or a pharmaceutically acceptable salt thereof, and an insulin secretagogue.

4. claims: 1-12, 23-25, (all partially), 18, 19

A method or pharmaceutical composition for glycaemic control in a mammal, comprising the administration of glutaminyl thiazolidine or glutaminyl pyrrolidine, or a pharmaceutically acceptable salt thereof, and an insulin sensitizer.

Intel nal Application No PCT/IB2004/003082

			-	101/18	2004/003082
Patent document cited in search report		Publication date		Patent family member(s)	Publication date
US 6548481	B1	15-04-2003	DE AT	19823831 A1 272059 T	02-12-1999 15-08-2004
			AT	271869 T	15-08-2004
			AT	289598 T	15-03-2004
			AT	231497 T	15-03-2003
			AU	764262 B2	14-08-2003
			AU	4370999 A	13-12-1999
			AU	2003262286 A1	11-12-2003
			BR	9910758 A	13-02-2003
			CA	2333603 A1	02-12-1999
			CN	1303381 A	11-07-2001
			DE	29909208 U1	
					09-09-1999
			DE	29909210 U1	09-09-1999
			DE	29909211 U1	23-09-1999
			DE	59904100 D1	27-02-2003
			DE	59910083 D1	02-09-2004
			DE	59910084 D1	02-09-2004
			DE	59911670 D1	31-03-2005
			MO	9961431 A1	02-12-1999
			EP	1215207 A2	19-06-2002
			EP	1214936 A2	19-06-2002
,			EP	1304327 A2	23-04-2003
			EP	1398030 A2	17-03-2004
			EP	1428533 A2	16-06-2004
			EP	1082314 A1	14-03-2001
			ES	2223981 T3	01-03-2005
			ES	2193709 T3	01-11-2003
			HK	1033316 A1	15-08-2003
			HU	. 0102001 A2	28-11-2001
			JP	2002516318 T	04-06-2002
			NO	20005994 A	25-01-2001
			NZ	508260 A	30-06-2003
			NZ	525799 A	. 24-09-2004
			PL	344403 A1	05-11-2001
•			RU	2227800 C2	27-04-2004
•			SI	1082314 T1	31-08-2003
		~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~	US 	2003134802 A1	17-07-2003
US 2003119736	A1	26-06-2003	US	2001051646 A1	13-12-2001
			US	2002198242 A1	26-12-2002
			US	2003008905 A1	09-01-2003
			US 	2005014703 A1	20-01-2005
US 2003162820	A1	28-08-2003	US	2004167191 A1	26-08-2004
			AU	2002325278 A1	09-09-2003
			BR	0215622 A	07-12-2004
			CA	2479812 A1	04-09-2003
			EP	1480961 A1	01-12-2004
			SK	3622004 A3	04-02-2005
			CA	2418543 A1	09-01-2003
			CA	2424645 A1	09-01-2003
			CN	1464881 A	31-12-2003
			CIA		
			CZ	20040973 A3	15-12-2004
			CZ DE	20040973 A3 20220238 U1	15-12-2004 08-05-2003
			CZ DE WO	20040973 A3 20220238 U1 03072556 A1	15-12-2004 08-05-2003 04-09-2003
			CZ DE WO WO	20040973 A3 20220238 U1 03072556 A1 03002595 A2	15-12-2004 08-05-2003 04-09-2003 09-01-2003
			CZ DE WO	20040973 A3 20220238 U1 03072556 A1	15-12-2004 08-05-2003 04-09-2003

Inter nel Application No PCT/IB2004/003082

Patent document cited in search report	Publication date		Patent family member(s)		Publication date
US 2003162820 A	1	EP	1399471	A2	24-03-2004
		JP	2004521149	T	15-07-2004
		JP	2004534836	T	18-11-2004
		NO	20030895	À	26-02-2003
		NO	20030896	A	16-04-2003
		US	2003119750	A1	26-06-2003
		US	2003130199	A1	10-07-2003
US 2003139434 A	1 24-07-2003	AU	3732101	Α	31-07-2001
		BR	0107715	Α	19-11-2002
		CA	2397554	A1	26-07-2001
		CN	1400908	Α	05-03-2003
		WO	0152825	A2	26-07-2001
		EP	1248604	A2	16-10-2002
		JP	2003520226	T	02-07-2003
DE 29924609 U	1 22-04-2004	NONE			
WO 2004031374 A	15-04-2004	US	2004058876	A1	25-03-2004
		ĂÜ	2003293311	—	23-04-2004
		WO	2004031374		15-04-2004